Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours.

CONCLUSIONS: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.
PMID: 30714538 [PubMed - as supplied by publisher]

Source: Current Radiopharmaceuticals - February 5, 2019 Category: Radiology Tags: Curr Radiopharm Source Type: research